NV3P Stock Overview
A clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
NanoViricides, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.22 |
52 Week High | US$3.02 |
52 Week Low | US$0.90 |
Beta | 0.97 |
11 Month Change | -4.69% |
3 Month Change | -29.07% |
1 Year Change | 12.96% |
33 Year Change | -69.39% |
5 Year Change | n/a |
Change since IPO | -97.45% |
Recent News & Updates
Recent updates
Shareholder Returns
NV3P | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.8% | 1.9% | 1.5% |
1Y | 13.0% | -15.1% | 8.8% |
Return vs Industry: NV3P exceeded the German Biotechs industry which returned -16.1% over the past year.
Return vs Market: NV3P exceeded the German Market which returned 7.8% over the past year.
Price Volatility
NV3P volatility | |
---|---|
NV3P Average Weekly Movement | 11.9% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NV3P's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NV3P's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 7 | Anil Diwan | www.nanoviricides.com |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
NanoViricides, Inc. Fundamentals Summary
NV3P fundamental statistics | |
---|---|
Market cap | €18.58m |
Earnings (TTM) | -€9.00m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs NV3P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NV3P income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$9.45m |
Earnings | -US$9.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.66 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NV3P perform over the long term?
See historical performance and comparison